Archer Aviation Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Archer Aviation Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $300.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Mar 2, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($618.20M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($536.80M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($457.90M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($317.30M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($347.80M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($10.85M) | May 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($729.30M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($509.70M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($446.90M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($347.40M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($358.30M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($229.9K) | May 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $493.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $357.70M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $276.40M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $171.50M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $64.30M | Feb 29, 2024 |
| FY2021 | Dec 31, 2020 | $21.10M | Mar 14, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($432.90M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($368.60M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($271.60M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($200.40M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($108.40M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($564.9K) | May 24, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.80M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $82.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $44.30M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $6.90M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $3.50M | Feb 29, 2024 |
| FY2021 | Dec 31, 2020 | $1.40M | Mar 14, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.47B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.00B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $554.30M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $573.80M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $768.40M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $41.80M | Mar 14, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $263.10M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $248.60M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $187.20M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $80.50M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $69.50M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $5.90M | Mar 14, 2022 |
| FY2020 | Oct 30, 2020 | $37.57M | May 24, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $752.60M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $367.10M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $493.30M | Mar 2, 2026 |
| FY2024 | Dec 31, 2021 | $698.90M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $35.90M | Feb 29, 2024 |
| FY2020 | Aug 25, 2020 | $0 | May 24, 2021 |
| FY2021 | Dec 31, 2019 | $4.90M | Mar 14, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.0K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 2, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.30B) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($1.69B) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($1.15B) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($690.90M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($373.60M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($25.80M) | Mar 14, 2022 |
| FY2020 | Oct 30, 2020 | ($788.4K) | May 24, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $834.50M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $464.60M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $69.40M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $746.60M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $36.60M | Mar 14, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.30M | Mar 2, 2026 |
| FY2024 | Dec 31, 2024 | $64.00M | Feb 28, 2025 |
| FY2024 | Dec 31, 2023 | $7.20M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $9.30M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $18.80M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $900.0K | Mar 14, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 29, 2024 |
| FY2021 | Dec 31, 2020 | 0 | Mar 14, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 29, 2024 |
| FY2021 | Dec 31, 2020 | 0 | Mar 14, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 744.05M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 503.78M | Mar 2, 2026 |
| FY2023 | Sep 16, 2021 | 232.64M | Feb 29, 2024 |
| FY2023 | Sep 15, 2021 | 59.85M | Feb 29, 2024 |